文献速递慢性肾脏病

慢性肾脏病新治疗进展综述

Updates on New Therapies for Patients with CKD.
PubMed 文献 · Kidney Int Rep · 2023-10-12

全球慢性肾脏病(CKD)患者持续增加,心血管事件风险显著高于一般人群,尽管遵循指南管理仍存在残余心肾风险。本综述讨论CKD病理生理及新型药物(ARNI、SGLT2i、GLP-1激动剂、finerenone)的获益与局限,并基于关键试验入选标准提出患者亚组选择算法。

要点

  • CKD患者心血管风险显著增高,现有指南管理下仍存在残余风险。
  • ARNI、SGLT2i、GLP-1激动剂和finerenone可改善CKD患者结局。
  • 基于关键试验标准选择患者亚组可能最大化新药获益。

核心结论

  • 新型药物如ARNI、SGLT2i、GLP-1激动剂和finerenone可能改变CKD治疗格局,但需认识其获益与挑战。
  • 基于关键试验入选标准,部分CKD亚组可能从这些药物中获益最大。

研究设计与样本

  • 本综述基于近期发表的研究,讨论CKD病理生理及新型药物的获益与局限。

主要发现

  • CKD患者心血管事件风险显著高于一般人群,尽管指南管理仍存在残余心肾风险。
  • ARNI、SGLT2i、GLP-1激动剂和finerenone在CKD患者中显示疗效。
  • 肾病范围蛋白尿超过5000 mg/g或血压控制不佳(收缩压≥160 mm Hg或舒张压≥100 mm Hg)的CKD患者研究不足。

关键数值与推荐

  • 肾病范围蛋白尿定义为尿蛋白超过5000 mg/g。
  • 血压控制不佳定义为收缩压≥160 mm Hg或舒张压≥100 mm Hg。

临床怎么用

  • 基于关键试验入选标准选择CKD患者亚组,可能最大化新型药物的获益。

局限性

  • 肾病范围蛋白尿超过5000 mg/g或血压控制不佳的CKD患者仍缺乏研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals diagnosed with chronic kidney disease (CKD) continue to increase globally. This group of patients experience a disproportionately higher risk of cardiovascular (CV) events compared to the general population. Despite multiple guidelines-based medical management, patients with CKD continue to experience residual cardiorenal risk. Several potential mechanisms explain this excessive CV risk observed in individuals with CKD. Several new drugs have become available that could potentially transform CKD care, given their efficacy in this patient population. Nevertheless, use of these drugs presents certain benefits and challenges that are often underrecognized by prescribing these drugs. In this review, we aim to provide a brief discussion about CKD pathophysiology, limiting our discussion to recent published studies. We also explore benefits and limitations of newer drugs, including angiotensin receptor/neprilysin inhibitors (ARNI), sodium glucose transporter 2 inhibitors (SGLT2i), glucagon-like peptides-1 (GLP-1) agonists and finerenone in patients with CKD. Despite several articles covering this topic, our review provides an algorithm where subgroups of patients with CKD might benefit the most from such drugs based on the selection criteria of the landmark trials. Patients with CKD who have nephrotic range proteinuria beyond 5000 mg/g, or those with poorly controlled blood pressure (systolic ≥160 mm Hg or diastolic ≥100 mm Hg) remain understudied.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Tarun T, Ghanta SN, Ong V, et al. Updates on New Therapies for Patients with CKD. Kidney Int Rep. 2023. PMID: 38312786. doi:10.1016/j.ekir.2023.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。